Danny Rischin
305 Grattan Street
Melbourne, VIC, Australia
Melbourne, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 175 publications
Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT).
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: February 23, 2026
Cemiplimab in the treatment of cutaneous squamous cell carcinoma.
Journal: Immunotherapy
Published: January 29, 2026
Adjuvant nivolumab for resected high-risk head and neck cancer.
Journal: Lancet (London, England)
Published: December 18, 2025
Adjuvant Cemiplimab in Cutaneous Squamous-Cell Carcinoma. Reply.
Journal: The New England journal of medicine
Published: November 12, 2025
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.
Journal: Cancer
Published: November 04, 2025
Evaluating CD103+ intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer.
Journal: Oral oncology
Published: October 29, 2025
Prognostic Subgroups for Disease-Free Survival With Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Secondary Analysis of a Randomized Clinical Trial.
Journal: JAMA otolaryngology-- head & neck surgery
Published: August 28, 2025
Cost-Effectiveness Analysis of Transoral Robotic Surgery Versus Radiotherapy Alone for Early-Stage HPV-Associated Oropharynx Squamous Cell Carcinoma in Australia.
Journal: Journal of medical imaging and radiation oncology
Published: August 11, 2025
Radiation Therapy Target Objectives for Tonsillar Cancer Treated With Unilateral Radiation Therapy-A Replanning Study From TROG 12.01.
Journal: International journal of radiation oncology, biology, physics
Published: August 07, 2025
Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma.
Journal: Current oncology (Toronto, Ont.)
Published: July 31, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors.
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: July 16, 2025
Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study.
Journal: Journal of the American Academy of Dermatology
Published: June 19, 2025
Last Updated: 09/26/2026